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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Purpose: The aim of the study was to analyse and compare the ability of multipara-
metric magnetic resonance imaging (mp–MRI) and prostate biopsy (PB) to correctly 
identify tumor foci in patients undergoing radical prostatectomy (RP) for prostate 
cancer (PCa).
Materials and Methods: 157 patients with clinically localised PCa with a PSA <10 ng/
mL and a negative DRE diagnosed on the first (12 samples, Group A) or second (18 
samples, Group B) PB were enrolled at our institution. All patients underwent mp-MRI 
with T2-weighted images, diffusion-weighted imaging, dynamic contrast enhanced-
-MRI prior to RP. A map of comparison describing each positive biopsy sample was 
created for each patient, with each tumor focus shown on the MRI and each lesion 
present on the definitive histological examination in order to compare tumor detection 
and location. The sensitivity of mp-MRI and PB for diagnosis was compared using 
Student’s t-test. The ability of the two exams to detect the prevalence of Gleason pat-
tern 4 in the identified lesions was compared using a chi-square test.
Results: Overall sensitivity of PB and mp-MRI to identify tumor lesion was 59.4% and 
78.9%, respectively (p<0.0001). PB missed 144/355 lesions, 59 of which (16.6%) were 
significant. mp-MRI missed 75/355 lesions, 12 of which (3.4%) were significant. No le-
sions with a GS≥8 were missed. Sensitivity of PB and mp-MRI to detect the prevalence 
of Gleason pattern 4 was 88.2% and 97.4%, respectively.
Conclusions: mp-MRI seems to identify more tumor lesions than PB and to provide 
more information concerning tumor characteristics.
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INTRODUCTION
In recent decades, an increase in prostate 
cancer (PCa) diagnosis occurred because of the 
introduction of PSA into clinical practice and an 
increase in the number of biopsy samples, leading 
to an increase in cases with low-grade disease on 
prostate biopsy (PB) and a pathological migration 
towards earlier stage tumors (1).
 After the diagnosis of PCa, some factors 
have a negative prognostic value, such as tumor 
volume (TV) and Gleason Score (GS). The cur-
rent definition of clinically significant disease is 
PCa with a TV≥0.5 mL and/or a pathologic GS >6 
(2, 3). To predict a significant PCa prior to sur-
gery, urologists use parameters such as the PSA 
value, digital rectal examination (DRE), and PB 
results (bioptic GS, number of positive samples 
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and percentage of biopsy cores positive for PCa), 
separately or in combination in nomograms (4). 
Despite the use of these tools, tumor size and 
aggressiveness are often underestimated (5). Re-
cently, some authors have emphasised the role 
of multiparametric magnetic resonance imaging 
(mp-MRI) in PCa diagnosis, taking advantage of 
the anatomical, morphological and functional 
information that it provides (6-8).
 The aim of this prospective study was to 
analyse the ability of mp-MRI to correctly identify 
tumor foci in patients undergoing radical prosta-
tectomy (RP) for PCa with a PSA <10 ng/mL and 
a negative DRE and to compare it with the results 
of PB. The secondary aims were to identify signifi-
cant or insignificant lesions and to compare the 
ability of these results dividing our population in 
terms of diagnosis at first or second PB.
MATERIALS AND METHODS
Population
 The study lasted between September 2010 
and November 2012, and it was approved by the 
ethical committee of our institution, San Luigi 
Hospital in Orbassano (Turin), Italy. During this 
period, 178 consecutive patients with PCa diag-
nosed on the first or second PB who underwent 
mp-MRI prior to RP, as a part of preoperative eva-
luation, were enrolled at our institution.
 For the purposes of the study, only pa-
tients with clinically localised PCa with a PSA <10 
ng/mL and a negative DRE were included. The 
exclusion criteria involved: any previous prostate 
treatment (TURP, 12 patients; hormonal therapy, 
4 patients); contraindications for mp-MRI (i.e., 
claustrophobia, presence of magnetically activa-
ted implanted devices, metallic implants in sensi-
tive areas; 5 patients). The patients were divided 
into two groups: Group A, patients diagnosed at 
the first biopsy; and Group B, patients diagnosed 
at the second biopsy.
Prostate biopsy
 All biopsies were performed at our ins-
titution with a transrectal approach under TRUS 
guidance. First biopsies consisted of 12 samples 
(Group A) while second biopsies consisted of 18 
samples (Group B). Second biopsies were perfor-
med in cases of an initial negative PB and per-
sistently elevated PSA, according to a systematic 
template. A modification of the European Consen-
sus Meeting on the prostate MRI template (9) was 
used for this purpose (Figure-1).
A B
Figure 1 - Prostate reporting scheme for first (A) and second (B) prostate biopsy with transrectal approach. Prostate gland is 
divided into 12 (A) or 18 (B) sectors.
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mp-MRI
 All patients underwent preoperative mp-
MRI in the Department of Radiology of I.R.C.C. 
in Candiolo, using a 1.5 Tesla unit (Signa HDX, 
General Electric, Milwaukee, USA), with a 4-chan-
nel phased-array body coil and an endorectal coil 
filled with 50 mL of air for signal reception, af-
ter intramuscular injection of 20 mg butylscopol-
amine bromide. All patients underwent mp-MRI at 
least 6 weeks after PB, to reduce artefacts due to 
bleeding or inflammation. All mp-MRI examina-
tions were performed according to the same pro-
tocol, using the following sequences: a panoramic 
T1-weighted sequence from the aortic bifurcation 
to the symphysis pubis for the evaluation of iliac 
and obturator lymphadenopathies; T2-weighted 
images (slice-thickness 3 mm, FOV 16 x 16 cm, 
NEX 2) and T1 fast spin-echo axial images (slice-
thickness 3 mm, TR/TE 580/min, FOV 16 x 16 cm, 
matrix 320 x 256, NEX 2) were used to study pros-
tate and seminal vesicles in axial (TR/TE 3020/85), 
coronal (TR/TE 3620/90) and sagittal (TR/TE 
3960/110) planes. Three sequences were obtained 
on Diffusion-Weighted Imaging (DWI), with ax-
ial EPI sequences (slice-thickness 3 mm, TR/TE 
7000/min., FOV 16x16 cm, matrix 128x128, NEX 
6) with b-values of 0.600 s/mm2, 0.1000 s/mm2 
and 0.1400 s/mm2. Dynamic Contrast Enhanced 
MRI (DCE-MRI) was performed using axial FSPGR 
sequences with a temporal resolution of 13s, re-
peated for 26 times (TR/TE ~3.5/min., FOV 20x20 
cm, matrix 224x192, NEX 0.5). The contrast agent 
(gadobutrol, Gadovist, Bayer Pharma AG, Berlin) 
was administered intravenously at an injection 
rate of 2 mL/s, followed by saline solution flush at 
the same rate using a power injector (Spectris, Me-
drad). The entire prostate was sectioned to achieve 
3 mm-thick parasagittal sections. All MRI images 
were interpreted by the same expert uroradiolo-
gist. Positivity for neoplastic tissue was defined by 
the following: hypointensity in T2-weighted (T2w) 
images; an Apparent Diffusion Coefficient (ADC) 
value ≤1.05 mm²/s with a b-value of 1000 s/mm² 
in DWI examination; an enhancing area with ear-
ly intense contrast uptake followed by washout in 
DCE-MRI. Overall, the mp-MRI finding was con-
sidered positive if at least two of the three MRI 
sequences (T2w, DWI and DCE-MRI) produced 
suspicious findings. The presence, side and loca-
tion of PCa were analysed, and for every lesion, 
the radiological stage, ADC and pharmacokinetic 
parameters were analysed using DCE-MRI. For the 
purpose of the study, very low ADC values were 
considered as an index of Gleason pattern 4 prev-
alence, based on the previously reported correla-
tion between ADC and GS (10).
RP
All patients underwent robot-assisted RP 
at our institution.
Pathologic analysis
 All RP specimens were uniformly pro-
cessed and submitted in their entirety for histo-
logical investigation according to the protocol of 
Montironi et al. (11). The entire prostate surface 
was treated with black ink, and the seminal vesi-
cles and the apical and basal portions of the gland 
were removed to create two 4 mm sections. From 
the remaining gland, 4 mm-thick parasagittal sec-
tions were obtained and were further sectioned 
to achieve 3 mm slices (analogous to slices ob-
tained with MRI), which were then stained with 
haematoxylin-eosin. Tumors were staged accord-
ing to the TNM classification system, and the 
grading was evaluated according to the Gleason 
Score (12). The volume of each tumor was meas-
ured using the ellipsoid formula (length x width x 
height x 0.52) in mL. The pathologic analysis was 
conducted by the same uropathologist who was 
blinded to the MRI results. The following variables 
were analysed: tumor location, TV, and pathologic 
GS (pGS).
Map of comparison
 A dedicated operator, blinded to patient 
names, noted the location of positive biopsy sam-
ples according to the European Consensus Meet-
ing on prostate MRI (9) on a specific form. The 
same procedure was performed by the radiologist 
for the MRI report and by the pathologist for the 
pathology report. A map describing each positive 
biopsy sample was created for each patient, with 
each tumor focus shown on the MRI and each le-
sion present on the definitive histological exami-
nation (Figure-2).
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Statistical analysis
 Using the tumor map obtained by the 
pathologic analysis as the standard reference, the 
overlap of the biopsy samples and mp-MRI was 
evaluated. Lesions were divided into groups ac-
cording to the TV (<0.5 and ≥0.5 mL), the tumor 
location (basal, equatorial and apical) and the pGS 
(≤6, 7a – 3+4, 7b – 4+3, ≥8). The sensitivity of 
mp-MRI and PB for diagnosis was compared us-
ing Student’s t-test in the overall population and 
in Groups A and B. Finally, the ability of the two 
exams to detect the prevalence of Gleason pattern 
4 in the identified lesions was recorded and com-
pared using a chi-square test. All statistical tests 
were performed using Statistic 7 software (Stat-
soft, Tulsa, Oklahoma) and p-values <0.05 were 
considered as statistically significant.
RESULTS
 The overall population consisted of 157 
patients: group A consisted of 113 patients diag-
nosed at the first prostate mapping, while group B 
Figure 2 - Example of two comparison maps between biopsy (a, a'), mp-MRI (b, b') and pathological examination (c, 
c'). The first case (1) was a naive patient with 12 PB samples (a), with a diagnosis of PCa in 3/12 samples on the right 
lobe (equatorial, equatorial lateral, basal lateral); mp-MRI (b) highlighted two areas that were suspicious for cancer: the 
posterolateral equatorial right with extension to the base (diameter 8x5 mm) and the anterolateral equatorial left (diameter 
4x5 mm); a histological examination of the surgical specimen (c) demonstrated two tumor foci: a right posterolateral lesion 
on the basal plane extending to the equatorial plane (vol. 0.75 mL) and a left anterolateral lesion on the equatorial plane 
(vol. 0.3 mL). The second case (2) was a patient with persistently elevated PSA from whom 18 samples were collected during 
a second PB (a'). A diagnosis of PCa was made in 3/12 samples from the left lobe (equatorial lateral, basal median, apical 
median); mp-MRI (b') highlighted two suspicious areas: the posterolateral left on the basal plane (diameter 6x4 mm) and the 
apical posterior (diameter 14x6 mm); a histological examination of the specimens (c') demonstrated two tumor foci: a left 
posterolateral lesion on the basal plane (vol. 0.45 mL) and a right posterolateral apical lesion extending to the contralateral 
lobe (vol. 1.25 mL).
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consisted of 44 patients diagnosed at the second 
prostate mapping. The baseline characteristics are 
detailed in Table-1.
 The pathologic analysis identified 355 ne-
oplastic lesions, 140 (39.4%) with a TV <0.5 mL 
and 215 (60.6%) with a TV ≥0.5 mL. The mean TV 
was 2.21±2.5 mL (median 1.55 mL; range 0.04-
15.3 mL). According to the pGS, 150 (42.3%) le-
sions had a GS ≤6, 148 (41.7%) GS=7a (3+4), 31 
(9%) GS=7b (4+3) and 26 (7%) a GS≥8. Tumor 
location was also analysed; 118 (33.2%) lesions 
were basal, 121 (34.1%) were equatorial, and 116 
(32.7%) were apical.
 Overall, MRI identified tumor lesions 
thanks to three sequences that produced suspi-
cious findings (T2w, DWI and DCE-MRI) in 69 
cases and thanks to two sequences in 211. In 36 
cases, only one sequence (T2w or DWI or DCE-
MRI) produced suspicious finding, so the lesion 
was not classified as tumour (see Materials and 
Methods section - mp MRI).
 The sensitivities of PB and mp-MRI for 
identifying tumor foci, stratified by TV, tumor lo-
cation and pGS, in the overall population and in 
the two subgroups are presented in Tables 2 and 3.
 PB missed 144/355 lesions, 59 of which 
(40.9%) were significant: 11 with a TV ≥0.5 mL, 25 
with a pGS=7 and 23 with both a TV ≥0.5 mL and 
a pGS=7. No statistically significant differences in 
the number of missed significant lesions were re-
corded between Groups A and B.
 mp-MRI missed 75/355 lesions, 12 of 
which (16%) were significant: four with a TV ≥0.5 
mL, six with a pGS=7 and two with both a TV ≥0.5 
mL and a pGS=7. No lesions with a GS ≥8 were 
missed by both mp-MRI and PB.
 Compared to PB, in the overall popula-
tion and in Groups A and B, mp-MRI demon-
strated a higher sensitivity, reaching statistical 
significance in most of stratifications. The results 
are detailed in Table-4.
 The abilities of mp-MRI and PB to detect 
the prevalence of Gleason pattern 4 are shown 
in Table-5.
 PB showed an accuracy, sensitivity, 
specificity, positive predictive value, and nega-
tive predictive value of 87.2%, 88.2%, 81.8%, 
96.3%, and 56.3%, respectively, while mp-MRI 
showed values of 97.5%, 97.4%, 98.0%, 99.6%, 
and 89.3%, respectively. Pearson’s correlation 
coefficients were 0.6067 and 0.9207 for PB and 
mp-MRI, respectively.
DISCUSSION
 After a diagnosis of localised PCa eligible 
for RP, the current standard of pre-operative evalu-
ation is based on data from biopsies of the entire 
Table 1 - Baseline characteristics. Group A= first biopsy (12 samples); Group B= second biopsy (18 samples); SD= standard deviation.
Overall population Group A Group B p-value
Number of patients 157 113 44 /
Age, mean (SD), years 63.1±6.2 63.2±6 63.1±6.8 NS
PSA, mean (SD), ng/mL 5.87±2.1 5.91±2 5.73±2.2 NS
Number of positive biopsy samples, median (range) 3 (1-12) 3 (1-8) 3 (1-12) NS
% pathological tissue, median (range) 13.5 (0.1-87) 12.5 (0.1-80) 14 (0.5-87) NS
Bioptic Gleason Score, rate (number of patients)
≤6 51.6%(81) 54.9%(62) 43.2%(19) NS
7a 37.6%(59) 36.3%(41) 40.9%(18) NS
7b 5.1%(8) 2.6%(3) 11.4%(5) NS
≥8 5.8%(9) 6.2%(7) 4.5%(2) NS
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Table 2 - Neoplastic lesions identified by prostate biopsy. Group A= first biopsy (12 samples); Group B= second biopsy (18 samples).
Prostate Biopsy
Identified overall Identified
Group A
Identified
Group B
p-value
Pathologic Tumor 
Volume 
<0.5 mL 21.4% (30/140) 20.8% (21/101) 23.1% (9/39) NS
≥0.5 mL 84.2% (181/215) 81.5% (123/151) 90.6% (58/64) NS
Pathologic Tumor 
Location
Basal 54.2% (64/118) 51.2% (43/84) 61.8% (21/34) NS
Equatorial 61.2% (74/121) 58.8% (50/85) 66.7% (24/36) NS
Apical 62.9% (73/116) 61.4% (51/83) 66.7% (22/33) NS
Pathologic Gleason 
Score
≤6 36.0% (54/150) 33.7% (36/107) 41.9% (18/43) NS
7a 73.0% (108/148) 71.7% (76/106) 76.2% (32/42) NS
7b 74.2% (23/31) 70.8% (17/24) 85.7% (6/7) NS
≥8 100% (26/26) 100% (15/15) 100% (11/11) NS
Total 59.4% (211/355) 57.1% (144/252) 65% (67/103) NS
Table 3 - Neoplastic lesions identified by mp-MRI. Group A= first biopsy (12 samples); Group B= second biopsy (18 samples).
mp-MRI
Identified overall Identified
Group A
Identified
Group B
p-value
Pathologic Tumor Volume <0.5 mL 50.7% (71/140) 49.5% (50/101) 53.9% (21/39) NS
≥0.5 mL 97.2% (209/215) 96.7%(146/151) 98.4% (63/64) NS
Pathologic Tumor Location Basal 71.2% (84/118) 71.4%(60/84) 70.6% (24/34) NS
Equatorial 84.3% (102/121) 83.5% (71/85) 86.1% (31/36) NS
Apical 81.0% (94/116) 77.4% (65/83) 87.9% (29/33) NS
Pathologic Gleason Score ≤6 55.3% (83/150) 53.3% (57/107) 60.5% (26/43) NS
7a 95.2% (141/148) 95.3%(101/106) 95.2%(40/42) NS
7b 96.8% (30/31) 95.8%(23/24) 100%(7/7) NS
≥8 100% (26/26) 100% (15/15) 100% (11/11) NS
Total 78.9% (280/355) 77.8% (196/252) 81.6% (84/103) NS
prostate gland under TRUS guidance. Thus, in 
men diagnosed with low-risk PCa, we observed an 
underestimation of the tumor grade in up to 30% 
of cases and the tumor burden in up to 50% of 
cases that was related to the biopsy technique, and 
it affected both the first and repeat biopsies (5). 
mp-MRI is the imaging technique that provides 
the best results for the diagnosis of significant 
PCa with high sensitivity and specificity values 
(7). Moreover, the use of an endorectal coil may 
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Table 4 - Comparison between sensitivity of prostate biopsy and mp-MRI in identifying tumor lesions. Results are reported by 
studied variables in the overall population and in Group A (first prostate biopsy) and B (second prostate biopsy).
Sensitivity PB mp-MRI p-value
Total Overall 59.4% 78.9% <0.0001
Group A 57.1% 77.8% <0.0001
Group B 65.0% 81.6% 0.0112
Pathologic 
Tumor Volume
<0.5 mL Overall 21.4% 50.7% <0.0001
Group A 20.8% 49.5% <0.0001
Group B 23.1% 53.9% <0.0001
>0.5 mL Overall 84.2% 97.2% <0.0001
Group A 81.5% 96.7% <0.0001
Group B 90.6% 98.4% 0.0316
Pathologic 
Tumor Location
Basal Overall 54.2% 71.2% 0.01
Group A 51.2% 71.4% 0.0114
Group B 61.8% 70.6% NS
Equatorial Overall 61.2% 84.3% 0.0001
Group A 58.8% 83.5% 0.0007
Group B 66.7% 86.1% NS
Apical Overall 62.9% 81.0% 0.0035
Group A 61.4% 77.4% 0.0386
Group B 66.7% 87.9% NS
Pathologic 
Gleason Score
≤6 Overall 36.0% 55.3% 0.0012
Group A 33.7% 53.3% 0.0059
Group B 41.9% 60.5% NS
7a Overall 73.0% 95.2% < 0.0001
Group A 71.7% 95.3% < 0.0001
Group B 76.2% 95.2% 0.0296
7b Overall 74.2% 96.8% 0.0291
Group A 70.8% 95.8% NS
Group B 85.7% 100% NS
≥8 Overall 100% 100% NS
Group A 100% 100% NS
Group B 100% 100% NS
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Table 5 - Comparison among PB and mp-MRI in predicting the prevalence of Gleason pattern 4 on histopathological analysis. 
The prevalence of pattern 4 is evaluated on histology and biopsy with the Gleason Score ≥7b (pGS and bGS, respectively) 
while is predicted in mp-MRI by a very low value of the ADC on DWI. Gleason pattern 4 not prevalent is defined by Gleason 
Score ≤7a. The rate (number) of identified patients are shown. In the lower part of the table the Pearson correlation coefficient, 
both for biopsy and mp-MRI, is indicated.
PB mp-MRI
Pattern 4
prevalent
Pattern 4
not prevalent
Pattern 4
prevalent
Pattern 4
not prevalent
Histology (standard reference) Pattern 4
prevalent
56.2% (27/48) 43.8% (21/48) 89.3% (50/56) 10.7% (6/56)
Pattern 4
not prevalent
3.7% (6/163) 96.3% (157/163) 0.4% (1/224) 99.6% (223/224)
Pearson’s correlation coefficient 0.6067 0.9207
allow a more accurate detection rate by improving 
the spatial characterisation of the prostate zonal 
anatomy and molecular changes (13). Actually, 
mp-MRI is also gaining an important role because 
of the possibility that it offers in performing cog-
nitive (14) or visually guided targeted PB (15-17). 
In this study, compared to transrectal biopsy, mp-
MRI demonstrated a significantly greater sensitiv-
ity in the entire study population (78.9% vs. 59.4%, 
p<0.001) and in each subgroup (TV, tumor location 
and pGS). Moreover, mp-MRI diagnosed the vast 
majority of significant lesions regarding TV (97.2% 
in PCa with TV ≥0.5 mL) and pGS (>95% in PCa 
with pGS ≥7). Although mp-MRI had a sensitiv-
ity that was statistically higher than biopsy, both 
had low sensitivity for detecting small lesions (TV 
<0.5 mL). The same results were observed when the 
population was divided into patients diagnosed at 
the first PB (Group A) or the second PB (Group B). 
Despite these differences between mp-MRI and PB, 
it is extremely important to identify the character-
istics of the missed lesions and determine whether 
these characteristics are actually significant.
 In our study, only 12 of the 75 lesions 
(16%) missed by mp-MRI were significant PCas 
(with a TV ≥0.5 mL and/or a GS ≥7), representing 
3.4% (12/355) of all identified lesions. Conversely, 
PB missed 144 lesions of which 40% (59/144) were 
significant (16.6% of all identified lesions). Inter-
estingly, all lesions with a GS ≥8 were diagnosed by 
both mp-MRI and PB.
 A change in GS from the PB to the resected 
specimen was recently reported in approximately 
23-35% of cases (18). Functional imaging tech-
niques provide information not just about tumor 
location and volume but also about cancer behav-
iour (8): less differentiated and dense cancers are 
associated with lower ADC values, better contrast 
and a higher detection rate using DWI (19, 20). 
Additionally, cancer foci show lower ADC values 
than normal prostate tissue, and these values cor-
relate with GS (10, 21). Nevertheless, ADC values 
may vary depending on the technical parameters 
used (10). In our study, we analysed the ability of 
mp-MRI to identify the prevalence of the path-
ologic Gleason pattern 4 and observed a strong 
correlation (Pearson 0.9207) between Gleason pat-
tern 4 and very low ADC values on DWI, while a 
good correlation was obtained using the biopsy 
GS (Pearson 0.6067).
 Focusing on clinically not significant dis-
ease, mp-MRI correctly identified 50% of tumor 
lesions with a TV <0.5 mL and 55% of PCa with 
a GS ≤6. In our opinion, on the basis of these re-
sults, mp-MRI may be a valid diagnostic tool not 
only before the surgery but also in the follow up 
of patients included in active surveillance proto-
cols for PCa.
 The technical parameters of mp-MRI used 
in this study correspond to the minimal imaging 
requirements outlined in the recommendations of 
the European Consensus Meeting on prostate MRI 
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(9), particularly concerning the use of an endorec-
tal coil (considered an optimal requirement).
 This study was limited by the inclusion of 
only a single expert uroradiologist who interpret-
ed all the mp-MRI images, which may affect the 
reproducibility of our results in centres without 
a radiologic team specialised in prostate mp-MRI. 
On the other hand, including only one uroradiolo-
gist minimises sources of potential bias because 
patients were treated and followed at the same de-
partment.
CONCLUSIONS
 Our study suggested that mp-MRI allo-
ws for higher identification rate of tumor lesions 
than PB. Moreover, compared to significant PCa 
diagnosed at either the first or second biopsy, mp-
-MRI provides more information concerning tu-
mor anatomy (tumor volume and location) and 
aggressiveness (prevalence of Gleason pattern 4). 
In patients with PCa with PSA <10 ng/mL and ne-
gative DRE, the data provided by mp-MRI may be 
useful for better therapeutic planning.
ABBREVIATIONS
PCa =  prostate cancer
PB = prostate biopsy
TV = tumor volume
GS = Gleason Score
DRE = digital rectal examination
mp-MRI = multiparametric Magnetic Resonance 
Imaging
RP = radical prostatectomy
DWI = Diffusion-Weighted Imaging
DCE = Dynamic Contrast Enhancement
ADC = Apparent Diffusion Coefficient
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